GeneBio and Goodlett Laboratory Launch Collaboration
Geneva Bioinformatics (GeneBio) SA and the Goodlett Laboratory of the University of Washington have announced a collaboration that will integrate GeneBio's Phenyx software platform for MS data analysis into the Goodlett
Laboratory's planned 200 node Multi-tiered Proteomics Compute (MPC) cluster.
GeneBio and the Goodlett Laboratory have already begun working together to enhance Phenyx' operation on the Laboratory's existing 40 node MPC, and the Laboratory expects to use Phenyx as their primary proteomics analysis engine.
Phenyx-generated identifications will be vetted by the Insilicos' Proteomics Pipeline, a tool supported through collaboration between Insilicos and GeneBio.
Dr. David R. Goodlett, Associate Professor of Medicinal Chemistry at the University of Washington announced, "We are excited about this collaboration and will use it as a starting point to further refine and develop our MS workflow."
"The Lab and GeneBio plan to work together on scientific projects of mutual interest; our own internal developments will go hand-in-hand with special developments on Phenyx to optimally adapt it to these projects, one of which includes running protein de novo folding software combined with MS/MS data interpretation. So, we expect this to be an extremely fruitful relationship."
"This partnership with the Goodlett Laboratory really shows with how much efficiency Phenyx has been fulfilling high proteomics expectations since its introduction in 2004," said Prof. Ron D. Appel, PhD, Chairman and Scientific Founder of GeneBio and head of the Proteome Informatics Group at the Swiss Institute of Bioinformatics.
"The results of our work together, including new scorings, feature ameliorations, and new developments in the field of proteomics will be used to further refine both the public and commercial versions of Phenyx, thus cementing our standing in the realm of MS search engines."
"A collaborative relationship with such a world-renowned laboratory is destined to produce some exciting results; I believe this will work out well for both GeneBio and the Goodlett Laboratory."